• 1
    Rowinsky EK, Donehower RC. Drug therapy: Paclitaxel (Taxol). N Engl J Med. 1995; 332: 10041014.
  • 2
    Tankanow RM. Docetaxel: a taxoid for the treatment of metastatic breast cancer. Am J Health Syst Pharm. 1998; 55: 17771791.
  • 3
    Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979; 277: 665667.
  • 4
    Schiff PB, Horwitz SG. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980; 82: 12471259.
  • 5
    Rowinsky EK, Cazenave LA, Donehower R. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990; 82: 12471259.
  • 6
    Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side effects. Cancer Treatment Rev. 1995; 21: 463478.
  • 7
    Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995; 22(Suppl 4): 316.
  • 8
    von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized controlled open phase IIb study. J Clin Oncol. 2001; 19: 35063515.
  • 9
    Hinton S, Catalano P, Einhorn LH, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2002; 20: 18591863.
  • 10
    Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002; 20: 35783585.
  • 11
    Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol. 2002; 20: 38573864.
  • 12
    Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002; 20: 23652369.
  • 13
    Choy H, Shur Y, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for non-small cell lung cancer in the U.S. Cancer. 2000; 88: 13361346.
  • 14
    Forsyth PA, Balmaceda C, Peterson K, et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997; 35: 4753.
  • 15
    Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002; 20: 13351343.
  • 16
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570579.
  • 17
    Calhoun EA, Fishman DA, Roland PY, et al. Validity and sensitivity of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity (FACT/GOG-Ntx). Proc Am Soc Clin Oncol. 2000; 19: 446a.
  • 18
    Cella D, Bonomi A, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995; 12: 199220.
  • 19
    Cohen J. Statistical power analysis for the behavioral sciences, 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers, 1988.
  • 20
    Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002; 55: 285295.
  • 21
    Wyrwich K, Tierney W, Wolinsky F. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999; 52: 861873.
  • 22
    Bennett KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade off and standard gamble techniques. In: SpilkerB, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd edition. Philadelphia: Lippincott-Raven, 1996: 253265.
  • 23
    Fairclough DL, Peterson H, Cella D, Bonomi P. Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials. Stat Med. 1998; 17: 781796.
  • 24
    Hahn EA, Webster KA, Cella D, Fairclough DL. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Stat Med. 1998; 17: 547559.